Anti-Angiogenic Agents in Management of Sarcoma Patients: Overview of Published Trials.
| Autor: | Cren PY; Lille University, Medical School, Lille, France., Lebellec L; Lille University, Medical School, Lille, France.; Medical Oncology Unit, Tourcoing Hospital, Tourcoing, France., Ryckewaert T; Medical Oncology Department, Centre Oscar Lambret, Lille, France., Penel N; Lille University, Medical School, Lille, France.; Medical Oncology Department, Centre Oscar Lambret, Lille, France. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Frontiers in oncology [Front Oncol] 2020 Nov 24; Vol. 10, pp. 594445. Date of Electronic Publication: 2020 Nov 24 (Print Publication: 2020). |
| DOI: | 10.3389/fonc.2020.594445 |
| Abstrakt: | We reviewed all fully published clinical trials assessing anti-angiogenic agents in sarcoma patients (last issue, January 13, 2020). Anti-angiogenic macromolecules (e.g., bevacizumab or ombrabulin) provide disappointing results. Many multikinase inhibitors have been assessed with non-randomized phase II trials with limited samples and without stratification according to histological subtypes, therefore interpretation of such trials is very challenging. On the contrary, pazopanib, regorafenib, and sorafenib have been assessed using double-blind placebo-controlled randomized phase II or phase III trials. Compared to placebo, sorafenib demonstrates activity in desmoid-type fibromatosis patients. Based on results of phase 3 trial, pazopanib had obtained approval for treatment of pretreated non-adipocytic soft tissue sarcoma. Regorafenib is currently assessed in several clinical settings and provides significant improvement of progression-free survival in pre-treated non-adipocytic soft tissue sarcoma and in advanced pretreated osteosarcoma. Multikinase inhibitors are a breakthrough in sarcoma management. Many trials are ongoing. Nevertheless, predictive factors are still missing. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer GG declared a past co-authorship with one of the authors NP to the handling editor. (Copyright © 2020 Cren, Lebellec, Ryckewaert and Penel.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|